ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for ddt Track real-time Director Deals activity on the London Stock Exchange (LSE)

MYIG Mydecine Innovations Group Inc

0.00
0.00 (0.00%)
- - Closed
Share Name Share Symbol Market Type Share ISIN Share Description
Mydecine Innovations Group Inc AQSE:MYIG Aquis Stock Exchange Ordinary Share CA62849F2008 Ordinary share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Mydecine Innovations Group Inc - Delisting From AQSE

21/03/2025 7:00am

UK Regulatory


Mydecine Innovations (AQSE:MYIG)
Historical Stock Chart


From Jan 2025 to Jul 2025

Click Here for more Mydecine Innovations Charts.
Mydecine Innovations Group Inc - Delisting From AQSE

PR Newswire

 

Delisting From AQSE

Vancouver, British Columbia, 21 March 2025 - Mydecine Innovations Group Inc. (the "Company") (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that, further to the announcement of 10 October 2024, its common shares will be withdrawn from trading on the Aquis Stock Exchange Growth Market with effect from market open on 2 April 2025.  Consequently, the last day of trading will be 1 April 2025 however the common shares will remain trading on the CSE, OTC and FSE.

 

The Directors of Mydecine take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

On behalf of the Board of Directors,

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch

Chief Executive Officer

contact@mydecineinc.com

 

AQSE Corporate Advisor

Novum Securities Limited  Tel: +44 (0)207 399 9400

David Coffman / Anastassiya Eley

 




1 Year Mydecine Innovations Chart

1 Year Mydecine Innovations Chart

1 Month Mydecine Innovations Chart

1 Month Mydecine Innovations Chart

Your Recent History

Delayed Upgrade Clock